Clinical results with irinotecan (CPT-11 [Camptosar]) and other camptothecin derivatives in various cancers, although encouraging, have fallen short of the expectations predicted by preclinical models. One proposed
Peter J. Houghton, PhD
Advertisement
Articles by Peter J. Houghton, PhD
Advertisement
Latest Updated Articles
- Extending Principles Learned in Model Systems to Clinical Trials Design
Published: August 1st 1998 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
2
Career Stage and Location Found to Impact Oncology Coverage in the US
3
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
